ACS APPLIED MATERIALS & INTERFACES

www.acsami.org

Addition/Correction

Correction to "Nanodiamonds Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases"

Nuseibah AL Qtaish,△ Idoia Gallego,△ Alejandro J. Paredes, Ilia Villate-Beitia, Cristina Soto-Sánchez, Gema Martínez-Navarrete, Myriam Sainz-Ramos, Tania B. Lopez-Mendez, Francisco Javier Chichón, Noelia Zamarreño, Eduardo Fernández, Gustavo Puras,* and José Luis Pedraz*

ACS Appl. Mater. Interfaces **2022**, *14* (11), 13665−13677. DOI: 10.1021/acsami.2c02182

Cite This: *ACS Appl. Mater. Interfaces* 2023, 15, 4857−4858

Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

In the original version of this article, the authors Francisco Javier Chichón and Noelia Zamarreño were incorrectly not included in the authorship. This Correction contains the corrected Authorship, Author Information (affiliations), Author Contributions, Acknowledgments, and Supporting Information. The changes do not alter the major conclusions of this work.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.2c18984.

Biophysical screening of the nanodiasome formulations composed of niosomes with nanodiamonds as helper component, physicochemical characterization of nanodiasomes at different ND/DOTMA mass ratios (including Figure S1 showing the data), transfection efficiency of nanodiasomes at different ND/DOTMA mass ratios, Figure S2 showing normalized percentages of EGFP positive live cells and cell viability, and description of the videos (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Gustavo Puras − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain;* orcid.org/0000-0002-1536-7601; Email: gustavo.puras@ehu.eus

José Luis Pedraz − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain;* orcid.org/0000-0002-3938-2267; Email: joseluis.pedraz@ehu.eus

Authors

Nuseibah AL Qtaish − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain;* orcid.org/0000-0001-5966-6155

Idoia Gallego − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain;* orcid.org/0000-0002-9312-8147

Alejandro J. Paredes − *Research and Development Unit in Pharmaceutical Technology (UNITEFA), CONICET and Department of Pharmaceutical Sciences, Chemistry Sciences Faculty, National University of Córdoba, X5000XHUA Córdoba, Argentina; School of Pharmacy, Queen's University Belfast, Medical Biology Centre, Belfast BT9 7BL Northern Ireland, U.K.;* orcid.org/0000-0002-0414-8972

Ilia Villate-Beitia − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain;*

Published: January 10, 2023



Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain; orcid.org/0000-0002-3738-7611

Cristina Soto-Sánchez − *Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Neuroprothesis and Neuroengineering Research Group, Institute of Bioengineering, Miguel Hernández University, 03202 Elche, Spain;* orcid.org/0000-0003-4447-5967

Gema Martínez-Navarrete − *Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Neuroprothesis and Neuroengineering Research Group, Institute of Bioengineering, Miguel Hernández University, 03202 Elche, Spain;* orcid.org/0000-0002-9795-2846

Myriam Sainz-Ramos − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain;* orcid.org/0000-0001-7266-5771

Tania B. Lopez-Mendez − *NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain; Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain;* orcid.org/0000-0001-5029-6549

Francisco Javier Chichón − *CryoEM CSIC Facility, Structure of Macromolecules Department, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain*

Noelia Zamarreño − *CryoEM CSIC Facility, Structure of Macromolecules Department, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain*

Eduardo Fernández − *Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Neuroprothesis and Neuroengineering Research Group, Institute of Bioengineering, Miguel Hernández University, 03202 Elche, Spain;* orcid.org/0000-0002-7052-6011

Complete contact information is available at: https://pubs.acs.org/10.1021/acsami.2c18984

Author Contributions

△N.A.Q. and I.G. contributed equally. J.L.P., G.P.: Conceived the project. N.A.Q, I.G., A.J.P., C.S.S., G.M.N., M.S.R., T.B.L.M., N.Z.: Performed the experiments. N.A.Q., I.G., I.V.B., F.J.C.: Analyzed the results. N.A.Q., I.G.: Wrote the paper. N.A.Q., I.G, A.J.P., I.V.B., C.S.S, G.M.N., F.J.C.: Visualization. All authors: Reviewed-edited. J.L.P., G.P., E.F.: Supervision and project administration. J.L.P.: Funding acquisition. All authors have given approval to the final version of the manuscript.

■ ACKNOWLEDGMENTS

The authors wish to thank the intellectual and technical assistance from the Drug Formulation Unit (U10) of the ICTS "NANBIOSIS" from the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) at the University of Basque Country (UPV/EHU). Technical and human support provided by SGIKER (UPV/EHU) is also gratefully acknowledged. I.V.B. and M.S.R. thank the University of the Basque Country (UPV/EHU) for the granted postdoctoral fellowship (ESPDOC19/47) and the granted pre-doctoral fellowship (PIF17/79), respectively. We acknowledge Rocio Arranz for access to the cryoEM CNB-CSIC facility in the context of the CRIOMECORR project (ESFRI-2019-01-CSIC-16).